|
1
|
Goulden R, Hoyle MC, Monis J, Railton D,
Riley V, Martin P, Martina R and Nsutebu E: qSOFA, SIRS and NEWS
for predicting inhospital mortality and ICU admission in emergency
admissions treated as sepsis. Emerg Med J. 35:345–349.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sittipo P, Lobionda S, Lee YK and Maynard
CL: Intestinal microbiota and the immune system in metabolic
diseases. J Microbiol. 56:154–162. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Frazier TH, DiBaise JK and McClain CJ: Gut
microbiota, intestinal permeability, obesity-induced inflammation,
and liver injury. JPEN J Parenter Enteral Nutr. 35 (5
Suppl):14S–20S. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Assimakopoulos SF, Triantos C, Thomopoulos
K, Fligou F, Maroulis I, Marangos M and Gogos CA: Gut-origin sepsis
in the critically ill patient: Pathophysiology and treatment.
Infection. 46:751–760. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Vaishnavi C: Translocation of gut flora
and its role in sepsis. Indian J Med Microbiol. 31:334–342.
2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lan C, Shi X, Guo N, Pei H and Zhang H:
Value of serum miR-155-5p and miR-133a-3p expression for the
diagnosis and prognosis evaluation of sepsis. Zhonghua Wei Zhong
Bing Ji Jiu Yi Xue. 28:694–698. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
8
|
Jeon BN, Kim HR, Chung YS, Na BR, Park H,
Hong C, Fatima Y, Oh H, Kim CH and Jun CD: Actin stabilizer TAGLN2
potentiates adoptive T cell therapy by boosting the inside-out
costimulation via lymphocyte function-associated antigen-1.
Oncoimmunology. 7(e1500674)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pei J, Li P, Zhang ZY, Zhang HL, Gao YH,
Wang DY, Zheng Y, Xu X and Cui JZ: Effect of TAGLN2 in the
regulation of meningioma tumorigenesis and development. Eur Rev Med
Pharmacol Sci. 22:307–313. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang H, Jiang M, Liu Q, Han Z, Zhao Y and
Ji S: miR-145-5p inhibits the proliferation and migration of
bladder cancer cells by targeting TAGLN2. Oncol Lett. 16:6355–6360.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Leung WK, Ching AK, Chan AW, Poon TC, Mian
H, Wong AS, To KF and Wong N: A novel interplay between oncogenic
PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of
liver cancer cell motility. Oncogene. 30:4464–4475. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Meng T, Liu L, Hao R, Chen S and Dong Y:
Transgelin-2: A potential oncogenic factor. Tumour Biol.
39(1010428317702650)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sato T and Clevers H: Primary mouse small
intestinal epithelial cell cultures. Methods Mol Biol. 945:319–328.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Arocho A, Chen B, Ladanyi M and Pan Q:
Validation of the 2-DeltaDeltaCt calculation as an alternate method
of data analysis for quantitative PCR of BCR-ABL P210 transcripts.
Diagn Mol Pathol. 15:56–61. 2006.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li AY, Yang Q and Yang K: miR-133a
mediates the hypoxia-induced apoptosis by inhibiting TAGLN2
expression in cardiac myocytes. Mol Cell Biochem. 400:173–181.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cecconi M, Evans L, Levy M and Rhodes A:
Sepsis and septic shock. Lancet. 392:75–87. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Salomao R, Ferreira BL, Salomao MC, Santos
SS, Azevedo LCP and Brunialti MKC: Sepsis: Evolving concepts and
challenges. Braz J Med Biol Res. 52(e8595)2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Berg D and Gerlach H: Recent advances in
understanding and managing sepsis. F1000Res 7: F1000 Faculty
Rev-1570, 2018.
|
|
19
|
Keeley A, Hine P and Nsutebu E: The
recognition and management of sepsis and septic shock: A guide for
non-intensivists. Postgrad Med J. 93:626–634. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Levi M and van der Poll T: Coagulation and
sepsis. Thromb Res. 149:38–44. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
van der Poll T, van de Veerdonk FL,
Scicluna BP and Netea MG: The immunopathology of sepsis and
potential therapeutic targets. Nat Rev Immunol. 17:407–420.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rhodes A, Evans LE, Alhazzani W, Levy MM,
Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally
ME, et al: Surviving sepsis campaign: International guidelines for
management of sepsis and septic shock: 2016. Crit Care Med.
45:486–552. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Amornphimoltham P, Yuen PST, Star RA and
Leelahavanichkul A: Gut leakage of fungal-derived inflammatory
mediators: Part of a gut-liver-kidney axis in bacterial sepsis. Dig
Dis Sci. 64:2416–2428. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Haak BW and Wiersinga WJ: The role of the
gut microbiota in sepsis. Lancet Gastroenterol Hepatol. 2:135–143.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Haak BW, Prescott HC and Wiersinga WJ:
Therapeutic potential of the gut microbiota in the prevention and
treatment of sepsis. Front Immunol. 9(2042)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chopra DP, Dombkowski AA, Stemmer PM and
Parker GC: Intestinal epithelial cells in vitro. Stem Cells Dev.
19:131–142. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chelakkot C, Ghim J and Ryu SH: Mechanisms
regulating intestinal barrier integrity and its pathological
implications. Exp Mol Med. 50(103)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vasilescu C, Rossi S, Shimizu M, Tudor S,
Veronese A, Ferracin M, Nicoloso MS, Barbarotto E, Popa M,
Stanciulea O, et al: MicroRNA fingerprints identify miR-150 as a
plasma prognostic marker in patients with sepsis. PLoS One.
4(e7405)2009.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Essandoh K, Li Y, Huo J and Fan GC:
miRNA-mediated macrophage polarization and its potential role in
the regulation of inflammatory response. Shock. 46:122–131.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang JF, Yu ML, Yu G, Bian JJ, Deng XM,
Wan XJ and Zhu KM: Serum miR-146a and miR-223 as potential new
biomarkers for sepsis. Biochem Biophys Res Commun. 394:184–188.
2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhou R, Huang W, Fan X, Liu F, Luo L, Yuan
H, Jiang Y, Xiao H, Zhou Z, Deng C and Dang X: miR-499 released
during myocardial infarction causes endothelial injury by targeting
alpha7-nAchR. J Cell Mol Med. 23:6085–6097. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tang Y, Pan J, Huang S, Peng X, Zou X, Luo
Y, Ren D, Zhang X, Li R, He P and Wa Q: Downregulation of
miR-133a-3p promotes prostate cancer bone metastasis via activating
PI3K/AKT signaling. J Exp Clin Cancer Res. 37(160)2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang Y, Ma J, Qiu W, Zhang J, Feng S, Zhou
X, Wang X, Jin L, Long K, Liu L, et al: Guanidinoacetic acid
regulates myogenic differentiation and muscle growth through
miR-133a-3p and miR-1a-3p Co-mediated Akt/mTOR/S6K signaling
pathway. Int J Mol Sci. 19(2837)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
He B, Lin X, Tian F, Yu W and Qiao B:
miR-133a-3p inhibits oral squamous cell carcinoma (OSCC)
proliferation and invasion by suppressing COL1A1. J Cell Biochem.
119:338–346. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jin LW, Ye HY, Xu XY, Zheng Y and Chen Y:
miR-133a/133b inhibits Treg differentiation in IgA nephropathy
through targeting FOXP3. Biomed Pharmacother. 101:195–200.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wei P, Xie Y, Abel PW, Huang Y, Ma Q, Li
L, Hao J, Wolff DW, Wei T and Tu Y: Transforming growth factor
(TGF)-β1-induced miR-133a inhibits myofibroblast differentiation
and pulmonary fibrosis. Cell Death Dis. 10(670)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kim HR, Kwon MS, Lee S, Mun Y, Lee KS, Kim
CH, Na BR, Kim BNR, Piragyte I, Lee HS, et al: TAGLN2 polymerizes
G-actin in a low ionic state but blocks Arp2/3-nucleated actin
branching in physiological conditions. Sci Rep.
8(5503)2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumour-suppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.PubMed/NCBI View Article : Google Scholar
|
